The purpose of this study is to evaluate recanalization treatments use, safety and efficacy at the acute phase of arterial ischemic stroke in pediatric patients
Arterial ischemic stroke outcomes benefited from the implementation of recanalization treatments (IV thrombolysis, endovascular treatments) and adapted management pathways in adult patients. Nevertheless randomized trials did not enroll patients under the age of 18 years old and data concerning these treatments in children are scarce. As it is much less frequent than in adults, recognition of stroke is often delayed in children. Consequently, acute phase trials are difficult to set up and perform. The phase I multicentric international prospective trial TIPS (Thrombolysis in Pediatric Stroke) was prematurely stopped because of poor enrollment. Published retrospective regional (Paris-Ile-de-France region, France) and national (Switzerland) studies addressed the feasibility of such treatments but, because of small samples (less than 20 patients in each study), efficiency and prognostic factors could not be addressed. Exhaustive retrospective studies in a definite geographic area but with a sufficient number of patients in a limited inclusion period would provide these crucial data and address these questions with good relevance and limited bias.
Study Type
OBSERVATIONAL
Enrollment
70
Necker- Enfants Malades Hospital
Paris, Paris, France
Acute management of stroke:
Median time from symptom onset to Imaging (minutes)
Time frame: 1 day
Acute management of stroke:
Median time from symptom onset to beginning of recanalization treatment (minutes)
Time frame: 1 day
Acute management of stroke:
Median door-to-needle delay (minutes)
Time frame: 1 day
Treatment-emergent adverse events:
Intracranial hemorrhage (yes/no)
Time frame: 7 days
Treatment-emergent adverse events:
clinically symptomatic (yes/no)
Time frame: 7 days
Treatment-emergent adverse events:
Peripheral hemorrhage (yes/no)
Time frame: 7 days
factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis
age of onset (year, months)
Time frame: 12 months
factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis
Mechanism of stroke (CASCADE classification)
Time frame: 12 months
factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
stroke location (name of artery territory)
Time frame: 12 months
factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis
time from symptom onset to beginning of recanalization treatment (minutes)
Time frame: 12 months
factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis
initial imagine ASPECT Alberta Stroke Program Early CT Score. score (units on an scale). The ASPECTS score is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery (MCA) stroke. I has also been adapted to be used with MR scans. All scale ranges : Segmental assessment of the MCA vascular territory is made and 1 point is deducted from the initial score of 10 for every region involved (caudate, putamen, internal capsule, nsular cortex, M1(anterior MCA cortex=frontal operculum), M2(MCA cortex lateral to insular ribbon=anterior temporal lobe), M3(posterior MCA cortex=posterior temporal lobe, M4(anterior MCA territory immediately superior to M1), M5(lateral MCA territory immediately superior to M2), M6(posterior MCA territory immediately superior to M3) For each scale, values better or worse : In adults, an ASPECTS score less than or equal to 7 predicts a worse functional outcome at 3 months as well as symptomatic hemorrhage
Time frame: 12 months
factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis
Association with :Modified Rankin Scale - mRS (Units on a scale)The mRS is a 6-point quantitative measure of functional independence. All scale ranges: 0=No symptoms at all 1. No significant disability despite symptoms; able to carry out all usual duties and activities 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance disability; requiring some help, but able to walk without assistance 3. Moderate 4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. Dead For each scales range, values better or worse : In the literature, good outcome is usually considered for patients with mRS \[0-2\]. Very good outcome is considered for patients with mRS \[0-1\]. We will use the same thresholds
Time frame: 12 months
factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis
Association with : \- The Pediatric Stroke Outcome Measure - PSOM (Units on a scale) =scale has been designed and published to quantify functional consequences of stroke in children. The PSOM is a detailed neurological examination, with outcome scored in terms of degree of impairment in each of language, cognition, and sensorimotor. We wil use the PSOM-SNE version (PSOM-Short Neuro Exam version). All scale ranges (0-0,5-1 or 2): \- Sensorimotor deficit, Language Deficit - Production, Language Deficit - Comprehension, Cognitive or Behavioural Deficit. Total score on 10 For each scale range, values better or worse: Total impairment scores (out of a maximum of 10) will be considered as previously published, i.e. total score 0 or 0.5 representing good outcome, and poor outcome ≥1. All subscales ranges (Normal, Anormal, Not Done): Level of consciousness, Behaviour, mental status, Language, Cranial nerves, Motor testing, Tendon reflexes, Fine motor coordination, Sensory, Gate
Time frame: 12 months